about
Emerging roles of Nrf2 signal in non-small cell lung cancerIn vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells.Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis.D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel deliveryA novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment.Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis.Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres.Relationship between the SER treatment period and prognosis of patients with small cell lung cancer.miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1.Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.Effectiveness of comprehensive social support interventions among elderly patients with tuberculosis in communities in China: a community-based trial.Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method.EGFR-TKIs resistance via EGFR-independent signaling pathways.Gut microbiome modulates efficacy of immune checkpoint inhibitors.[Progress of platelet derived grow factor family in non-small cell lung cancer].EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastasesThe role of neoantigen in immune checkpoint blockade therapyThe role of gut microbiota in immune checkpoint inhibitor therapyActivating cGAS-STING pathway for the optimal effect of cancer immunotherapySynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentTargeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cellsThe efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysisGut microbiome and cancer immunotherapyProgrammed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of actionAdvances and perspectives of PARP inhibitorsDisparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective studyImmune pressures drive the promoter hypermethylation of neoantigen genesBlocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint InhibitorA novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cellsMolecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
P50
Q28078928-7627DF00-69DD-4C38-99E3-915587E45684Q28541936-4E219ABA-86CE-4855-BCBA-18AF0713B993Q34374689-F9590760-29E2-472A-A666-EFA4A88487DBQ34712645-ACC6B580-8E13-4060-B8F2-FEEEF3E134BBQ35677519-D2DCF6CC-4167-4DC7-8A90-7588B053413EQ35994325-DB39F6BE-5EB8-4B0A-A2A4-D6E63D32EE1AQ36951434-8D845F3B-62C2-40D5-A848-E432AC11DE3DQ37233557-C0D2EDEB-6D2A-4166-AADC-717A77545B2BQ40942354-01023300-E9DF-4479-966E-E5692A14896CQ41916292-613B1F75-CD15-4085-864B-273B08D428D5Q43640353-D2720FBD-69E9-4BF8-A9D8-1D9B5C10533FQ45863941-8DB6F72E-79AF-4664-A739-FCB2ED7CC155Q47370729-4F694111-0806-4A5F-AD93-1AA610F6A1B2Q47556923-77F657CE-BAF6-4111-A2A2-E05F83DD2D59Q47748869-3CC08CFB-0AD4-4487-9B44-04CBB5252DB3Q49887890-CFD87452-F4C3-41B3-8920-D7AED2C9FDAFQ55240704-C9E8FCD0-E025-4D1A-B8FF-D8A8906FA3C0Q55464615-3E9CC749-56F7-408B-A8B2-2867D874014BQ58616450-74BB8BCC-4984-4B4A-BE85-44E9F6D6EC01Q59339934-93A41E2C-C136-4C0F-83A8-5F47F42F79FAQ60922499-42094116-CB45-46D4-A611-06F97F33B21AQ64094537-43242D79-D1DE-474F-8AD8-06C7BECBFEF5Q64100389-3D0EF347-A018-4C0B-B6EB-94863E8EA205Q90703496-94AB781C-32EB-4F9E-A6F7-3D90C69E8318Q91047410-F0589BD5-ECD7-4B18-94B0-EA18784E4E1AQ91233584-64F43310-AAA6-4598-A7BE-A2D028DD6164Q91275476-380810A4-44CC-444F-A89C-FD72FB62E80CQ91318710-EF5AB811-E260-4C88-8C42-7C44384A63C1Q91489770-95032920-DED3-4DD0-8A60-2AF037DFD30EQ91674484-52219CCE-DCB7-49E8-A5AF-1C477E0FA35DQ91737804-E8E77390-9FC7-48EF-B882-E4E0B934586DQ92621615-1D3DA01E-52B3-4433-BB0D-EFF337AD18B6Q92836667-539CC100-2B94-4FFD-8E22-FC8A507B8074
P50
description
researcher (ORCID 0000-0001-8192-7630)
@en
wetenschapper
@nl
name
Qian Chu
@en
Qian Chu
@nl
type
label
Qian Chu
@en
Qian Chu
@nl
prefLabel
Qian Chu
@en
Qian Chu
@nl
P31
P496
0000-0001-8192-7630